Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Cubist Pharmaceuticals

(

CBST

) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day up 1.3%. By the end of trading, Cubist Pharmaceuticals fell $2.00 (-2.8%) to $68.76 on light volume. Throughout the day, 955,665 shares of Cubist Pharmaceuticals exchanged hands as compared to its average daily volume of 1,275,400 shares. The stock ranged in price between $68.35-$71.09 after having opened the day at $70.71 as compared to the previous trading day's close of $70.76. Other companies within the Health Care sector that declined today were:

Mast Therapeutics

(

MSTX

), down 39.9%,

Prima Biomed

(

PBMD

), down 16.0%,

Genvec

(

GNVC

), down 9.5% and

Ariad Pharmaceuticals

(

ARIA

), down 8.8%.

Cubist Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of pharmaceutical products for various medical needs in the acute care environment in the United States. Cubist Pharmaceuticals has a market cap of $4.9 billion and is part of the drugs industry. The company has a P/E ratio of 204.7, above the S&P 500 P/E ratio of 17.7. Shares are up 55.8% year to date as of the close of trading on Monday. Currently there are 10 analysts that rate Cubist Pharmaceuticals a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates

Cubist Pharmaceuticals

as a

hold

. The company's strengths can be seen in multiple areas, such as its revenue growth, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and weak operating cash flow.

On the positive front,

Echo Therapeutics

TST Recommends

(

ECTE

), up 72.9%,

Zalicus

(

ZLCS

), up 29.8%,

Alimera

(

ALIM

), up 19.1% and

Veracyte

(

VCYT

), up 13.2% , were all gainers within the health care sector with

Covidien

(

COV

) being today's featured health care sector leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider

Health Care Select Sector SPDR

(

XLV

) while those bearish on the health care sector could consider

ProShares Ultra Short Health Care

(

RXD

).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

null